PNU-100766-d8

PNU-100766-d8 is deuterated labeled Linezolid (HY-10394) . Linezolid (PNU-100766) is the first member of the class of oxazolidinone synthetic antibiotic. Linezolid acts by inhibiting the initiation of bacterial protein synthesis. Linezolid is used for the treatment of serious infections caused by Gram-positive bacteria that are resistant to several other antibiotics[1][2][3].

Product Specifications

CAS Number

[1032182-14-1]

Product Name Alternative

PNU-100766-d8

UNSPSC

12352005

Hazard Statement

H372

Target

Antibiotic; Bacterial; Isotope-Labeled Compounds

Type

Isotope-Labeled Compounds

Related Pathways

Anti-infection; Others

Applications

COVID-19-immunoregulation

Field of Research

Infection

Purity

99.74

Solubility

10 mM in DMSO

Smiles

CC(NC[C@H]1CN(C2=CC=C(N3C([2H])([2H])C([2H])([2H])OC([2H])([2H])C3([2H])[2H])C(F)=C2)C(O1)=O)=O

Molecular Formula

C16H12D8FN3O4

Molecular Weight

345.40

Precautions

H372

References & Citations

[1]Clemett D, Markham A. Linezolid. Drugs. 2000 Apr;59 (4) :815-27; discussion 828.|[2]Chiappini E, Conti C, Galli L et al. Clinical efficacy and tolerability of linezolid in pediatric patients: a systematic review. Clin Ther. 2010 Jan;32 (1) :66-88.|[3]Perry CM, Jarvis B. Linezolid: a review of its use in the management of serious gram-positive infections. Drugs. 2001;61 (4) :525-51.|[4]He MZ, Jiang YW, Cai C. Mechanisms and epidemiology of linezolid resistance in staphylococci.Zhonghua Jie He He Hu Xi Za Zhi. 2012 May;35 (5) :360-2.|[5]Karau MJ, Tilahun AY, Schmidt SM, Clark CR, Patel R, Rajagopalan G. Linezolid is Superior to Vancomycin in Experimental Pneumonia Caused by Superantigen-Producing Staphylococcus aureus in HLA class II Transgenic Mice. Antimicrob Agents Chemother. 2012 Jul 30.|[6]Russak EM, et al. Impact of Deuterium Substitution on the Pharmacokinetics of Pharmaceuticals. Ann Pharmacother. 2019 Feb;53 (2) :211-216.